Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Nectero EAST System klinisk studie (stAAAble)

23. september 2026 oppdatert av: Nectero Medical, Inc.

Randomisert kontrollert klinisk utprøving (RCT) av Nectero EAST-systemet for små til mellomstore abdominale aortaaneurismer (AAA) StaBiLisering: Evaluering av effektivitet.

The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment. The main question the study aims to answer is to demonstrate efficacy of the product for stabilization of these small to mid-sized AAA.The study will compare the treatment group to the typical standard of care for these patients, surveillance. All subjects will be followed at designated intervals at 30/60 days, 6, 12, 18 and 24 months with continued follow-up annually for up to 5 years.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

400

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • New South Wales
      • Randwick, New South Wales, Australia, 2031
        • Rekruttering
        • Prince of Wales Private Hospital- POW Vascular Institute
        • Hovedetterforsker:
          • Ramon Varcoe
        • Ta kontakt med:
    • Arizona
      • Scottsdale, Arizona, Forente stater, 85258
        • Rekruttering
        • Honor Health Scottsdale Shea Medical Center
        • Hovedetterforsker:
          • Hasan Aldailami, MD
        • Ta kontakt med:
          • HonorHealth Cardiovascular Research
          • Telefonnummer: 480-323-1046
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Aktiv, ikke rekrutterende
        • University of Colorado
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20010
        • Rekruttering
        • Medstar Washington Hospital Center
        • Hovedetterforsker:
          • Steven Abramowitz, MD
        • Ta kontakt med:
        • Ta kontakt med:
    • Florida
    • Georgia
      • Augusta, Georgia, Forente stater, 30912
        • Rekruttering
        • Medical College of Georgia
        • Hovedetterforsker:
          • William Jordan, MD
        • Ta kontakt med:
        • Ta kontakt med:
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
        • Rekruttering
        • University of Chicago
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ross Milner, MD
      • Elk Grove, Illinois, Forente stater, 60007
        • Har ikke rekruttert ennå
        • Ascension Alexian Brothers
        • Hovedetterforsker:
          • Jack Chamberlin, MD
    • Maine
      • Scarborough, Maine, Forente stater, 04074
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Rekruttering
        • Massachusetts General Hospital
        • Hovedetterforsker:
          • Nikolaos Zacharias, MD
        • Ta kontakt med:
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Beth Israel Deaconess Medical Center
        • Hovedetterforsker:
          • Marc Schermerhorn, MD
        • Ta kontakt med:
        • Ta kontakt med:
      • Worcester, Massachusetts, Forente stater, 01655
        • Rekruttering
        • University of Massachusetts
        • Ta kontakt med:
        • Hovedetterforsker:
          • Andres Schanzer, MD
    • Michigan
      • Royal Oak, Michigan, Forente stater, 48073
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University School of Medicine
        • Hovedetterforsker:
          • Luis Sanchez, MD
        • Ta kontakt med:
    • Nebraska
      • Omaha, Nebraska, Forente stater, 68198
        • Rekruttering
        • University of Nebraska Medical Center
        • Hovedetterforsker:
          • Jonathan Thompson, MD
        • Ta kontakt med:
    • New Hampshire
      • Lebanon, New Hampshire, Forente stater, 03766
        • Rekruttering
        • Dartmouth Hitchcock Medical Center
        • Hovedetterforsker:
          • Rebecca Scully, MD
        • Ta kontakt med:
    • New York
      • Rochester, New York, Forente stater, 14642
      • Stony Brook, New York, Forente stater, 11794
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke University Medical Center
        • Hovedetterforsker:
          • Chandler Long, MD
        • Ta kontakt med:
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45219
      • Cleveland, Ohio, Forente stater, 44106
        • Rekruttering
        • University Hospitals Cleveland
        • Hovedetterforsker:
          • Jae Cho, MD
        • Ta kontakt med:
      • Cleveland, Ohio, Forente stater, 44195
        • Rekruttering
        • Cleveland Clinic
        • Hovedetterforsker:
          • Francis Caputo, MD
        • Ta kontakt med:
      • Columbus, Ohio, Forente stater, 43210
        • Rekruttering
        • The Ohio State University Wexner Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kristine Orion, MD
      • Columbus, Ohio, Forente stater, 43214
        • Rekruttering
        • Ohio Health Riverside
        • Hovedetterforsker:
          • Joseph Campbell, MD
        • Ta kontakt med:
    • Oklahoma
      • Tulsa, Oklahoma, Forente stater, 74104
        • Rekruttering
        • Oklahoma Heart Institute
        • Hovedetterforsker:
          • Julia Chen, MD
        • Ta kontakt med:
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • Rekruttering
        • Portland VA Medical Center
        • Hovedetterforsker:
          • Matthew Koopmann, MD
        • Ta kontakt med:
    • Pennsylvania
      • Bethlehem, Pennsylvania, Forente stater, 18015
        • Rekruttering
        • St. Luke's University Health Network
        • Hovedetterforsker:
          • Sharvil Sheth, MD
        • Ta kontakt med:
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Hospital of the University of Pennsylvania
        • Ta kontakt med:
        • Hovedetterforsker:
          • Grace Wang, MD
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Rekruttering
        • Jefferson Clinical Research Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael Nooromid, MD
      • Pittsburgh, Pennsylvania, Forente stater, 15219
        • Rekruttering
        • University of Pittsburgh Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Raymond Eid, MD
    • South Carolina
    • South Dakota
      • Sioux Falls, South Dakota, Forente stater, 57108
        • Rekruttering
        • North Central Heart - A Division of Avera Heart Hospital
        • Hovedetterforsker:
          • Michael Bacharach, MD
        • Ta kontakt med:
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37232
      • Nashville, Tennessee, Forente stater, 37212
        • Har ikke rekruttert ennå
        • VA Tennessee Valley Healthcare System
        • Hovedetterforsker:
          • John Curci, MD
        • Ta kontakt med:
    • Texas
      • Houston, Texas, Forente stater, 77004
      • Plano, Texas, Forente stater, 75093
        • Rekruttering
        • Baylor Scott & White Medical Center
        • Hovedetterforsker:
          • William Shutze, MD
        • Ta kontakt med:
    • Utah
      • Salt Lake City, Utah, Forente stater, 84132
        • Rekruttering
        • University of Utah Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Cali Johnson, MD
    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
        • Rekruttering
        • Inova Fairfax Medical Campus Inova Health Systems
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kendal Endicott, MD
      • Norfolk, Virginia, Forente stater, 23507
        • Rekruttering
        • Sentara Health
        • Hovedetterforsker:
          • David Dexter, MD
        • Ta kontakt med:
    • Washington
      • Seattle, Washington, Forente stater, 98104
        • Rekruttering
        • University of Washington at Harborview Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Benjamin Starnes, MD
    • Wisconsin
      • Green Bay, Wisconsin, Forente stater, 54301
      • Auckland, New Zealand, 1023
        • Rekruttering
        • Auckland City Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Andrew Holden, A/Prof

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

21 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Males and females ≥21 to ≤85 years of age. Females must be of non-childbearing potential (menopause or sterilization).
  2. Subject understands the purpose of the trial, agrees to voluntarily participate in the trial, signs the informed consent and is willing to complete the follow-up according to the requirements of the protocol.
  3. Infrarenal atherosclerotic fusiform abdominal aortic aneurysm from 3.5 cm to 5.0 cm (male) and 3.5 cm to 4.5 cm (female).
  4. Infrarenal aortic neck ≥ 15 mm in length and ≤ 29 mm in diameter.
  5. Overall AAA treatment length (distal renal to distal inferior margin of the aneurysm) not to exceed 130 mm.
  6. Iliac and femoral artery access, vessel size and morphology allow endovascular access of 14F (or larger) introducer sheaths and catheters.
  7. Subject meets American Society of Anesthesiology (ASA) grade 1 through 3 criteria, inclusive.
  8. Subject has > three-year life expectancy.
  9. Subject is able and willing to comply with all required follow-up clinic visits including CT scans (pre-randomization, 6, 12, 18, 24 months and annually up to 5 years) and blood draws.

Exclusion Criteria:

  1. Subject has an acutely ruptured, leaking, dissecting or emergent aneurysm.
  2. Subject has a symptomatic infrarenal abdominal aortic aneurysm.
  3. Subject has a mycotic or infected aneurysm.
  4. Subject has current vascular injury due to trauma.
  5. Subject's aneurysm is thoracic, suprarenal or juxtarenal.
  6. Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm.
  7. Subject has anatomy of diffuse, ulcerated, or extensive (shaggy) thrombus in the neck of the AAA, that in the opinion of the vascular surgeon/investigator, could result in embolization of the thrombus.
  8. Subject has anatomy of calcification, and/or plaque within the ilio-femoral arteries or severe infrarenal neck angulation that may compromise or does not allow delivery of the Introducer Sheath or the delivery catheter of the Nectero EAST System.
  9. Subject has had a myocardial infarction within six (6) months prior to enrollment or elevated CK enzymes or troponin indicative of an evolving MI prior to procedure.
  10. Subject has current angina, unstable angina, or other active cardiac condition such as congestive heart failure III and IV, atrial arrhythmia, ventricular arrhythmia, or valvular disease, requiring intervention.
  11. Subject has undergone other major surgery within the 30 days prior to enrollment.
  12. Subjects with any transient ischemic attack (TIA) or ischemic stroke within 3 months.
  13. Known allergy to contrast material that cannot be adequately premedicated, delivery system materials (i.e., nylon, polyurethane) and/or pentagalloylglucose (PGG).
  14. Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta.
  15. Subject has connective tissue/collagen disorder (e.g., Marfan syndrome, vascular Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome, Eaton Syndrome, Bessel-Hagen disease, etc.).
  16. Known contraindication to undergoing angiography or receiving systemic anticoagulation during the procedure.
  17. Subject has active systemic infection.
  18. Subject is participating in another research trial that could interfere with the results of the trial (e.g., drug trial).
  19. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from participation in the trial and to undergo the procedures and evaluations pre- and post-treatment.
  20. Subject has dialysis dependent renal failure or baseline serum creatinine level >2.5mg/dL or eGFR < 45 mL/min/1.73m2.
  21. Subjects with aminotransferase (ALT and/or AST) which is ≥1.5x upper limit of normal (ULN) or TB that is our of normal range for the evaluating laboratory.
  22. Subjects that may not tolerate the lowering of their systolic blood pressure to approximately 100mmHg, should not be considered for this study or treated using the Nectero EAST System.
  23. Subjects that may not be able to tolerate transient occlusion of the aorta should not be considered for this study.
  24. Subjects with saccular AAA.
  25. Subjects with rapidly expanding AAA (previous diameter increases of ≥0.5 cm in 6-months or ≥1 cm in 1 year) as these should be evaluated for immediate repair.
  26. Subjects who are not suitable for the Nectero EAST System treatment, as determined by the investigator.
  27. Subjects with INR out of normal range for the evaluating laboratory for a subject not on anti-coagulant therapy; or INR >3 for a subject on anti-coagulant therapy.
  28. Subjects with active/acute or a history of unstable chronic liver disease or current liver disease including but not limited to liver transplant, known genetic disorders such as Gilbert syndrome or other liver diseases.
  29. Subjects with cirrhosis (e.g., known history or new clinical diagnosis by elastography with a fibrosis score of F3 or F4 and/or steatosis grade of S3).
  30. Subjects with uncontrolled alcohol use disorder or current alcohol use putting them at risk of liver disease: including consumption of above one standard drink per day for women and two standard drinks per day for men.
  31. Subjects with known right-sided heart failure or pathologically dilated inferior vena cava or hepatic veins indicative of congestive hepatopathy.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Treatment Arm

Participants assigned to the treatment arm will undergo an endovascular procedure using the Nectero EAST System to deliver the Stabilizer Infusion Solution directly inside the aneurysm. This is a one-time local delivery of the product. Following treatment, surveillance of their AAA will be conducted using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years.

Intervention: Drug: Stabilizer

Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug.

Ingen inngripen: Control Arm

Participants assigned to the control arm will undergo surveillance of their AAA using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Primary Endpoint
Tidsramme: 24 months

The primary endpoint is the composite of all AAA-related death, rupture and repair (open-surgical, EVAR, or clinically indicated for repair as adjudicated by a committee of clinical experts blinded to the assigned arm).

24 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Growth
Tidsramme: 24 months

The growth over time in aneurysm diameter based on CT core laboratory readings.

24 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Daniel Clair, MD, Vanderbilt University Medical Center
  • Hovedetterforsker: Grace Wang, MD, University of Pennsylvania

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. oktober 2023

Primær fullføring (Antatt)

30. juni 2028

Studiet fullført (Antatt)

31. desember 2032

Datoer for studieregistrering

Først innsendt

7. august 2023

Først innsendt som oppfylte QC-kriteriene

14. august 2023

Først lagt ut (Faktiske)

21. august 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. september 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere